|Bid||14.22 x 800|
|Ask||14.25 x 1800|
|Day's range||13.76 - 14.52|
|52-week range||1.92 - 19.36|
|Beta (5Y monthly)||1.34|
|PE ratio (TTM)||N/A|
|Earnings date||11 May 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||16.00|
Inovio Pharmaceuticals (NASDAQ: INO) shares climbed 22.6% in May, according to data from S&P Global Market Intelligence, as investors cheered the rapid development of its coronavirus vaccine and as the company published positive preclinical data. Inovio in late April said it completed enrollment of 40 healthy volunteers in a phase 1 trial for its coronavirus vaccine and said it expects preliminary data in late June. The company last month announced the publication of preclinical data showing strong neutralizing antibody and T-cell immune responses in animal models.
The coronavirus vaccine race offers these clinical stage companies an opportunity to bring a first product to market -- if all goes well in human trials.
As the fallout from the coronavirus pandemic continues, the search for a vaccine is not slowing down.
Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) for breaches of fiduciary duties and violations of the Securities Exchange Act of 1934. Inovio is a late-stage biotechnology Company that focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines.
Novavax announced it would begin human trials for its coronavirus vaccine, while COVID-19 engulfs Brazil.
Biotech firm Novavax has entered its coronavirus vaccine in a Phase 1 clinical trial in Australia — the first in the Southern Hemisphere.
Vaccines are perceived as key to ending the restraints on work and life that have decimated the global economy, and returning to some sense of normalcy.
"We saw antibody responses that do many of the things we would want to see in an eventual vaccine," said Dr. David Weiner, director of the vaccine and immunotherapy center at the Wistar Institute, which has collaborated with Inovio. There are currently no approved treatments or vaccines for COVID-19, the disease caused by the new coronavirus, with governments, drugmakers and researchers working on around 100 vaccine programs. Many other drugmakers including Moderna Inc, Pfizer Inc, Johnson & Johnson, Sanofi and AstraZeneca Plc are also in various stages of vaccine development.
(Bloomberg) -- Millennium Management LLC was among hedge funds to pile millions into drug developers chasing a vaccine for the novel coronavirus.The money manager snatched up about 1.7 million shares of Inovio Pharmaceuticals Inc. and more than 600,000 shares of Moderna Inc. in the first quarter, according to a regulatory filing this week. The Inovio stake, worth about $23 million, makes the hedge fund the biotech’s eighth-largest holder, data compiled by Bloomberg show.Other investors that dipped their toes in Inovio or added to existing stakes were Balyasny Asset Management LP, Renaissance Technologies LLC and Bayesian Capital Management LP, while DE Shaw & Co. LP sold out of its more than 400,000 share stake. Viking Global Investors LP, an early investor in Moderna, dumped more than 2.3 million shares in the quarter ending March 31. DE Shaw also sold most of its stake in Moderna.Millennium also bought a 1.1% stake in Novavax Inc., a third company seeking a vaccine for Covid-19. The drug developer has racked up millions in funding from government agencies.Moderna is preparing for mid- and late-stage studies of its vaccine with plans to start the Phase 3 trial in early summer. Inovio, which just behind Moderna, kicked off a vaccine trial in April and aims to start larger studies this summer.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
If you're interested in Inovio Pharmaceuticals, Inc. (NASDAQ:INO), then you might want to consider its beta (a measure...
RBC Capital analyst Gregory Renza maintained a Hold rating on Inovio Pharmaceuticals (NASDAQ:INO) on Monday, setting a price target of $9, which is approximately 24.37% below the present share price of $11.9.
One welcome sign with the COVID-19 pandemic is how many companies, both large and small, have scrambled to develop diagnostic tests, antiviral treatments, and vaccines. Sure, these companies are in business to make money and have a profit motive behind their efforts. Inovio Pharmaceuticals (NASDAQ: INO) ranks as one of the leaders in the race to develop a COVID-19 vaccine.
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until May 12, 2020 to file lead plaintiff applications in a securities class action lawsuit against Inovio Pharmaceuticals (NasdaqGS: INO), if they purchased the Company’s shares between February 14, 2020 and March 9, 2020, both dates inclusive (the "Class Period"). This action is pending in the United States District Court for the Eastern District of Pennsylvania.
Inovio Pharmaceuticals (NASDAQ: INO) shares soared 61.7% in April, according to data provided by S&P Global Market Intelligence, as the company began human trials of its coronavirus vaccine. Inovio started a phase 1 trial of its DNA vaccine for COVID-19, the illness caused by the novel coronavirus, early in April and completed enrollment of 40 healthy adults later in the month. The clinical stage company also said it expanded its agreement with Richter-Helm BioLogics GmbH & Co. of Germany to cover large-scale manufacturing of the vaccine.
Robbins Geller Rudman & Dowd LLP announces that a securities class action lawsuit has been filed in the Eastern District of Pennsylvania on behalf of purchasers of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) common stock between February 14, 2020 and March 9, 2020 (the "Class Period"). The case is captioned McDermid v. Inovio Pharmaceuticals, Inc., No. 20-cv-01402, and is assigned to Judge Gerald J. Pappert. The Inovio Pharmaceuticals securities class action lawsuit charges Inovio Pharmaceuticals ("Inovio") and its current Chief Executive Officer J. Joseph Kim ("Kim") with violations of the Securities Exchange Act of 1934.
Inovio Pharmaceuticals (NASDAQ: INO) is on a lot of investors' radar screens these days. Genetronics change its name to Inovio in 2005 with its acquisition of Norwegian gene delivery technology company Inovio AS.
After shareholder pushback against its initial vaccine candidate announcement in February, Inovio badly needs its fraught clinical trial to succeed.
Inovio Pharmaceuticals' (NASDAQ: INO) SARS-CoV-2 vaccine candidate, INO-4800, is only in phase 1 development, but the biotech is already preparing to produce it at scale through a partnership with the German contract manufacturer Richter-Helm BioLogics.
Based on recent performance, Inovio would win in a knockout. Its shares have more than quadrupled in 2020 so far, while GlaxoSmithKline stock is down year to date. There's one big reason Inovio has been sizzling hot this year -- its COVID-19 vaccine program.